with the variables ages over 52 years (p ¼ 0.041), menopause (p ¼ 0.029) were the most susceptible to IUE permanence. ICIQ-SF variation average in group B was 9,625 points and in group C was 6,5 points. Presence of uterine prolapse implicated in increasing up to 4,75 points in average on post-operation ICIQ-SF (p¼0,03). VAS satisfaction average was higher in group B (8,84AE1,12) than in group C(5,5AE3,27). IGP-I showed better results in group B when compared to group C (p¼0,065).
INTRODUCTION AND OBJECTIVES:
To evaluate the longterm outcomes of the tension-free vaginal tape (TVT) procedure, we investigated the data from female patients with stress urinary incontinence (SUI) who had a minimum of 15 years of follow-up to determine the predictive risk factors affecting the treatment efficacy.
METHODS: A total of 192 female patients (mean AE SD age: 62.1 AE 7.8 years) who had undergone the TVT procedure for SUI were selected and followed-up for at least 15 years (mean AE SD duration: 191.4 months, . We analyzed the long-term results and the predictive parameters for success rates, and patients 0 satisfaction.
RESULTS: At 15 years after surgery, the overall cure rate was 84.5%, with a satisfaction rate of 68.4%. Univariate analysis showed an association between the SUI symptom grade and the cure rates, while the presence of frequency, urgency, and urge incontinence showed an association with the patients 0 satisfaction. However, in the multivariate logistic regression model, none of these variables were identified as an independent risk factor related to the cure and satisfaction rates. Twenty patients (10.0%) had postoperative complications at 1 year after surgery. However, at 15-years after surgery, only 2 patients (1.0%) had a postoperative complication, such as de novo urgency.
CONCLUSIONS: Our long-term data show that the TVT procedure is a reliable method for the treatment of female SUI, regardless of any independent predictive factors.
Source of Funding: None

PD50-06
MID-URETHRAL POSITION: IS THIS CRITICAL TO ACHIEVING CONTINENCE FOLLOWING SLING PLACEMENT FOR STRESS INCONTINENCE?
Janine Oliver*, Taylor Sadun, Claire Burton, Lauren Wood, Evgeniy Kreydin, Ja-Hong Kim, Shlomo Raz, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Since the widespread adoption of the synthetic mesh mid-urethral sling (MUS) for the treatment of stress urinary incontinence (SUI), proper placement of the sling at the mid urethra has been emphasized. There is limited and conflicting evidence on the importance of the mid-urethral position with regards to continence outcomes, however. We aimed to describe our experience of sling position in women presenting for MUS excision.
METHODS: We retrospectively reviewed our database of patients who underwent translabial ultrasound (TLUS) prior to MUS excision for mesh-related complications between January 2013 and May 2014 at UCLA. Patients were excluded if they had a history of pelvic radiation, neurogenic voiding dysfunction, transvaginal mesh placement for prolapse, urethral erosion, multiple slings, prior revision of an anti-SUI surgery, post-void residual > 150 cc, or did not undergo preoperative urodynamics (UDS). Patients were stratified into 2 cohorts based on absence or presence of SUI on UDS. Sling position was categorized as proximal urethra or bladder neck, mid urethra, or distal urethra based on sagittal images of the TLUS. Sling position was assessed by a radiologist. For cases in which the sling position overlapped between more than one location, the dominant location was determined by a FPMRS fellow (JO).
RESULTS: 96 patients were identified. Median age was 56.4 years old (range 32-83). Median time from last mesh placement to MUS excision was 4.76 years (1.4-13.6). Among 19 patients without SUI on UDS, the sling was located in the distal, mid, and proximal urethra in 19 (24.7%), 43 (55.8%), and 15 (19.5%) patients, respectively. Among 77 patients with SUI on UDS, the sling was located in the distal, mid, and proximal urethra in 4 (21.1%), 13 (68.4%), and 2 (10.5%) patients, respectively. Comparing the distribution of slings located at the mid urethra versus outside of the mid urethra, there was no significant difference between the cohorts (p¼0.4). There were also no significant differences in age, prior vaginal deliveries, or time to MUS excision. Patients presenting with SUI had a significantly higher body mass index (p¼0.02), however.
CONCLUSIONS: Many patients who have a successful outcome following MUS as defined as resolution of SUI have a sling located outside of the mid urethra. Thus, mid-urethral position may not be as critical to achieving continence with a MUS as previously thought. We hypothesize that it is the ability of a MUS to provide a 00 hammock 00 of support, regardless of position, that contributes to successful continence outcomes.
Source of Funding: None
PD50-07 LOW SERUM TESTOSTERONE IS ASSOCIATED WITH INCREASED STRESS AND MIXED INCONTINENCE IN WOMEN
Michelle Kim*, Boston, MA; Zaid Chaudhry, Janine Oliver, Evgeniy Kreydin, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Androgen receptors are present in the levator ani and testosterone administration has been shown to result in levator hypertrophy and improvement of surgically induced incontinence in a rodent model.1 However, the association between serum testosterone levels and incontinence in humans has not been extensively studied. We sought to examine the relationship between serum total testosterone levels and self reported urinary incontinence among women participating in a national survey.
METHODS: Data were analyzed for 2123 females who participated in the 2012 cycle of National Health and Nutrition Examination Survey and underwent measurement of serum total testosterone. Incontinence was defined as self-reported stress, urge, or mixed incontinence. Serum testosterone concentrations were log-transformed, assigned to quartiles, and examined first in a weighted variance-corrected univariate model for association with incontinence, and then in a weighted variance-corrected model adjusted for age, body mass index, diabetes, race, parity and time of venipuncture (morning, day, or evening).
RESULTS: Univariate analysis revealed a strong inverse correlation between serum testosterone level and each type of incontinence in females. However, after adjustment for age, decreased serum testosterone was associated only with increased likelihood of stress and mixed incontinence. In the multivariate model, women in the lowest quartile of serum testosterone concentration were more likely to Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e981 complain of stress (OR 1.49, 95%CI 1.07-2.06) and mixed incontinence (OR 1.61, 95%CI 1.18-2.18). CONCLUSIONS: This is the first study to demonstrate a relationship between serum testosterone level and stress and mixed incontinence in women. Given the role of pelvic musculature in maintaining urethral support and the anabolic effect of androgens on skeletal muscle, a physiologic mechanism for this relationship can be proposed and further evaluated in prospective and translational studies. METHODS: Analysis includes data from women enrolled in Cook MyoSite-sponsored SUI studies who underwent prior continence surgery (e.g., urethral sling, bladder neck suspension) and presented with incontinence episode frequency (IEF) of !3 stress leaks over 3 days and !3 g 24-hour pad test. Twenty-one women who received 1 treatment of 10 (n¼5), 50 (n¼2), 100 (n¼4), or 200 x 10 6 (n¼10) AMDC-USR were treated in open-label studies (NCT00847535, NCT01008943) and 17 women who were randomized 2:1 to receive 150 x 10 6 AMDC-USR (n¼11) or placebo (n¼6) and 1:1 for 1 or 2 treatments were treated in a double-blind trial (RCT, NCT01382602). SUI was assessed by 3-day diaries at baseline and 1, 3, 6, and 12 months for all studies and at 2 years in the RCT. RCT patients were unblinded after 12-month visits.
Source of
RESULTS: Median baseline stress IEF per 3 days was 12 leaks for open-label studies, and 11 leaks for AMDC-USR and 27.5 leaks for placebo in the RCT. In the RCT, the AMDC-USR group tended to be younger (51 yr vs. 64 yr), had a lower percentage with stage 1-2 pelvic organ prolapse (9% vs. 67%), and better 24-hour pad tests (45 g vs. 76 g) than placebo. In open-label studies, 18 women completed 12-month visits; 67% (12/18) had !50% IEF reduction, 44% (8/18) had !75% IEF reduction, and 39% (7/18) reported 1 leak over 3 days. Similarly, 12month responder rates for the RCT AMDC-USR group were 73% (8/11) for !50% IEF reduction, 64% (7/11) for !75% IEF reduction, and 36% (4/11) for 1 leak per 3 days. During the RCT, a higher percentage of the AMDC-USR group met IEF reduction endpoints than placebo (Figure) . Eight AMDC-USR RCT patients completed 2-year diaries; 100% (6/6) of women with !50% IEF reduction at 12 months also met the endpoint at 2 years. All (6/6) RCT placebo patients elected to receive open-label AMDC-USR after unblinding; at final follow-up, 3 patients had !50% IEF reduction compared to 12-month diaries. No AMDC-USR safety signals were identified.
CONCLUSIONS: AMDC-USR may be a novel, safe, durable therapy for the challenging patient population with recurrent or persistent SUI after continence surgery. As the efficacy of pharmacotherapy for SUI is generally unsatisfactory, surgery seems to be the best option for achieving long-term continence. Thus, new effective drugs for SUI should be developed. Tramadol is widely used as an analgesic. It combines the effects of m-opioid receptors with inhibition of serotonin and noradrenaline reuptake inhibitors. Both effects may be useful for treatment of SUI, but the efficacy of tramadol for SUI has not been examined yet. We previously established a rat model that can be used for examining the active urethral closure mechanism during sneezing. We therefore investigated the effect of tramadol on urethral continence reflex by using this model. METHODS: Healthy female rats and rats with SUI induced by vaginal distension (VD) were used. (1) The effects of tramadol on tilt leak point pressure (tilt LPP) were examined before and after intravenous (i.v.) injection of tramadol under urethane anesthesia in both rats.
(2) To investigate the effect of tramadol on mid-urethral responses during sneezing, the amplitude of the urethral responses during sneezing (A-URS) and urethral baseline pressure (UBP) were measured by inserting a microtip transducer catheter in the middle urethra in both rats. (3) To confirm the effects of tramadol on m-opioid receptors in the spinal cord, the effect of tramadol in the presence of intrathecal (i.t.) cyprodime, a selective m-opioid receptor antagonist, was examined in the healthy rats.
RESULTS: (1) Tilt LPP was lower in the VD rats than in the healthy rats (43.9 vs 48.6 cmH2O). Tramadol (i.v.) significantly increased the tilt LPP by 25.9% and 21.2% in the healthy and VD rats, respectively. (2) In the healthy rats, tramadol (i.v.) enhanced the A-URS and UBP by 37.0% and 74.9%, respectively. In the VD rats, tramadol administration also enhanced UBP by 11.1% but did not affect A-URS.
(3) Administration of cyprodime alone (i.t.) did not affect A-URS and UBP. However, in the presence of cyprodime, tramadol-induced increases in A-URS were suppressed, while UBP was elevated significantly.
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